Vivek Verma

Title: Vivek Verma: Innovator in Immune Therapy Resistance Detection

Introduction

Vivek Verma is a notable inventor based in Augusta, GA (US). He has made significant contributions to the field of immunotherapy, particularly in the detection and treatment of immune therapy resistance. His innovative work has the potential to enhance the effectiveness of cancer treatments.

Latest Patents

Vivek Verma holds a patent titled "Methods for detecting and reversing immune therapy resistance." This patent provides compositions and methods for detecting and treating anti-PD1 therapy resistance. The invention includes compositions that immunospecifically bind and deplete dysfunctional T cells, such as CD38PD-1T cells and CD38CD8T-cells. The patent outlines methods for depleting these dysfunctional T cells using antibodies or fusion proteins that specifically target them. Additionally, it describes a method for detecting and treating anti-PD1 therapy resistance by measuring the levels of CD38+PD1+CD8 T cells in blood or tissue samples prior to therapy.

Career Highlights

Vivek Verma is associated with the Augusta University Research Institute, Inc., where he continues to advance his research in immunotherapy. His work is crucial in addressing challenges faced in cancer treatment, particularly regarding therapy resistance.

Collaborations

Vivek collaborates with esteemed colleagues such as Samir N Khleif and Seema Gupta. Their combined expertise contributes to the innovative research being conducted at the Augusta University Research Institute.

Conclusion

Vivek Verma's contributions to the field of immunotherapy through his patent on detecting and reversing immune therapy resistance highlight his role as a significant inventor. His work promises to improve treatment outcomes for patients facing challenges with anti-PD1 therapy.